Recurrent Injury, Death Common After Acute Firearm Injury

THURSDAY, Aug. 31, 2023 (HealthDay News) -- Recurrent injury and death are common among acutely firearm-injured patients in the United States, according to a study published online Aug. 29 in the Annals of Internal Medicine.
Kristen L. Mueller, M.D., from Washington University in St. Louis, and colleagues examined the incidence and factors associated with recurrent firearm injuries and death among 9,553 consecutive adult and pediatric patients presenting with an acute, nonfatal firearm injury.
The researchers found that 1,155 patients experienced a recurrent firearm injury during a median follow-up of 3.5 years, including five firearm suicides and 149 fatal firearm injuries. Persons experiencing recurrent injury were young (25.3 ± 9.5 years), mostly male (93 percent), Black (96 percent), and uninsured (50 percent). The majority lived in areas of high social vulnerability (65 percent). The estimated risk for firearm injury at one and eight years was 7 and 17 percent, respectively.
"These data provide robust estimates of the burden of recurrent firearm injury and highlight the need for cross-sector data sharing to support firearm injury reduction," the authors write. "Accurate estimates of recurrence rates enhance both the ability to design appropriate violence intervention programs and to evaluate their real-world effectiveness, yet few studies have addressed firearm injury recurrence."
One author disclosed ties to the pharmaceutical industry.
Related Posts
¿Podría la obesidad atenuar la respuesta a la vacuna contra la COVID?
VIERNES, 6 de mayo de 2022 (HealthDay News) -- La obesidad puede complicar el...
¿Tiene menos de 45 años y prediabetes? Su riesgo de ataque cardiaco aumenta
LUNES, 16 de mayo de 2022 (HealthDay News) -- Si usted es un adulto joven con...
Dermatologist Visits Shorter for Asian Psoriasis Patients
MONDAY, Aug. 8, 2022 (HealthDay News) -- Asian patients with psoriasis receive...
Fracasa otro importante ensayo sobre una vacuna contra el VIH
JUEVES, 19 de enero de 2023 (HealthDay News) -- El único ensayo en etapa...
